Comment le ratio PE de CSL se compare-t-il à celui de ses pairs ?

CSL offre un bon rapport qualité-prix en fonction de son ratio Price-To-Earnings ( 32.2 x) par rapport à la moyenne des pairs ( 56.9 x).

Comment le ratio PE de CSL se compare-t-il à celui d'autres entreprises du secteur Global Biotechs ?

CSL est cher en fonction de son ratio Price-To-Earnings ( 32.2 x) par rapport à la moyenne du secteur Global Biotechs ( 26.3 x).

Quel est le ratio PE de CSL par rapport à son ratio équitable PE? Il s'agit du ratio PE attendu, compte tenu des prévisions de croissance des bénéfices de l'entreprise, des marges bénéficiaires et d'autres facteurs de risque.

CSL est cher en fonction de son ratio Price-To-Earnings ( 32.2 x) par rapport au ratio équitable Price-To-Earnings estimé ( 31.9 x).

Quel est le juste prix de CSL si l'on considère ses flux de trésorerie futurs ? Pour cette estimation, nous utilisons un modèle d'actualisation des flux de trésorerie.

CSL ( A$272.45 ) se négocie en dessous de notre estimation de la [[juste valeur]] ( A$408.13 )

Quelles sont les prévisions à 12 mois des analystes et avons-nous une confiance statistique dans l'objectif de prix du consensus ?

Le prix cible est supérieur de plus de 20 % au cours actuel de l'action et les analystes se situent dans une fourchette d'accord statistiquement confiante.

CSL (ASX:CSL) - Cours de l'action, nouvelles et analyse

CSL Aperçu des actions

CSL analyse fondamentale
Score flocon de neige
Évaluation	4/6
Croissance future	3/6
Performances passées	5/6
Santé financière	4/6
Dividendes	4/6

Récompenses

Se négocie à 33.2% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 13% par an

Les bénéfices ont augmenté de 20.4% au cours de l'année écoulée

Les analystes s'accordent à dire que le prix des actions augmentera de 20.3%

Analyse des risques

A un niveau d'endettement élevé

CSL Limited Concurrents

Telix Pharmaceuticals

ASX:TLX

AU$7.6b

Clinuvel Pharmaceuticals

ASX:CUV

AU$677.8m

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$81.4b

Amgen

NasdaqGS:AMGN

US$152.4b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour CSL
Historique des cours de bourse
Prix actuel de l'action	AU$272.45
Plus haut sur 52 semaines	AU$313.55
Plus bas sur 52 semaines	AU$255.17
Bêta	0.30
1Variation sur 1 mois	-9.36%
Variation sur 3 mois	-11.61%
Variation sur 1 an	5.76%
3Variation sur 3 ans	-13.80%
Variation sur 5 ans	-0.35%
Évolution depuis l'introduction en bourse	33,956.59%

Nouvelles et mises à jour récentes

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Recent updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Rendement pour les actionnaires

	CSL	AU Biotechs	AU Marché
7D	-5.2%	-2.6%	-0.07%
1Y	5.8%	11.2%	16.9%

Rendement vs Industrie: CSL a sous-performé le secteur Australian Biotechs qui a rapporté 11.2 % au cours de l'année écoulée.

Rendement vs marché: CSL a sous-performé le marché Australian qui a rapporté 16.9 % au cours de l'année écoulée.

Volatilité des prix

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.0%
Biotechs Industry Average Movement	10.1%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.4%

Cours de l'action stable: CSL n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de CSL ( 2% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited recherche, développe, fabrique, commercialise et distribue des produits biopharmaceutiques et des vaccins en Australie, aux États-Unis, en Allemagne, au Royaume-Uni, en Suisse, en Chine, à Hong Kong et dans le monde entier. La société opère à travers les segments CSL Behring, CSL Seqirus et CSL Vifor. Le segment CSL Behring propose des produits plasmatiques, des thérapies géniques et des recombinants.

CSL Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de CSL se comparent-ils à sa capitalisation boursière ?
CSL statistiques fondamentales
Capitalisation boursière	AU$131.92b
Bénéfices(TTM)	AU$4.09b
Recettes(TTM)	AU$22.92b

32.2x

Ratio P/E

5.8x

Ratio P/S

Le site CSL est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
CSL compte de résultat (TTM)
Recettes	US$14.80b
Coût des recettes	US$7.10b
Marge brute	US$7.71b
Autres dépenses	US$5.06b
Les revenus	US$2.64b

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

Feb 10, 2025

Résultat par action (EPS)	5.46
Marge brute	52.06%
Marge bénéficiaire nette	17.85%
Ratio dettes/capitaux propres	54.2%

Quelles ont été les performances à long terme de CSL?

Voir les performances historiques et les comparaisons

Dividendes

1.5%

Rendement actuel des dividendes

48%

Ratio de distribution

CSL Aperçu des actions

Récompenses

Analyse des risques

CSL Limited Concurrents

ASX:TLX

AU$7.6b

ASX:CUV

AU$677.8m

NasdaqGS:REGN

US$81.4b

NasdaqGS:AMGN

US$152.4b

Historique des prix et performances

Nouvelles et mises à jour récentes

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases